View ValuationMapLight Therapeutics 향후 성장Future 기준 점검 0/6MapLight Therapeutics 의 수익은 연간 5.5% 감소할 것으로 예상되는 반면, 연간 수익은 82.9% 로 증가할 것으로 예상됩니다. EPS는 연간 19.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -82.5% 로 예상됩니다.핵심 정보-5.5%이익 성장률19.45%EPS 성장률Biotechs 이익 성장25.2%매출 성장률82.9%향후 자기자본이익률-82.53%애널리스트 커버리지Good마지막 업데이트21 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesRecent Insider Transactions Derivative • May 05Founder notifies of intention to sell stockChristopher Kroeger intends to sell 236k shares in the next 90 days after lodging an Intent To Sell Form on the 4th of May. If the sale is conducted around the recent share price of US$30.70, it would amount to US$7.3m. For the year to December 2023, Christopher's total compensation was 3% salary and 97% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2025, Christopher's direct individual holding has increased from 6.02k shares to 325.10k. Company insiders have collectively sold US$674k more than they bought, via options and on-market transactions in the last 12 months.공시 • May 04MapLight Therapeutics Announces Completion of Enrollment In Zephyr Phase 2 Trial And Updates Expected Timing of Topline ResultsMapLight Therapeutics, Inc. announced completion of enrollment in its Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia. The Company also announced completion of the final patient visit in its Phase 2 IRIS trial evaluating ML-004 for the treatment of autism spectrum disorder. The Company expects to report topline results from both Phase 2 trials by mid-August 2026. The Phase 2 ZEPHYR trial is a randomized, double-blind, placebo-controlled trial evaluating the efficacy, safety, and tolerability of ML-007C-MA in inpatient adult participants with schizophrenia experiencing an acute exacerbation of psychosis. 307 participants in the trial were randomized 1:1:1 to receive either placebo, ML-007C-MA 210/3 mg twice daily, or ML-007C-MA 330/6 mg once daily. Primary endpoint is the change in PANSS total score from baseline to Week 5. Key secondary endpoints include change in CGI-S score, PANSS-Marder positive and negative factor scores from baseline to Week 5. Exploratory endpoints include change in cognitive function, assessed across multiple domains commonly impacted in schizophrenia, from baseline to Week 5. The Phase 2 IRIS trial is a randomized, double-blind, placebo-controlled trial evaluating the efficacy, safety, and tolerability of ML-004 in adults and adolescents with autism spectrum disorder. 161 participants were randomized in the trial, consistent with enrollment target of over 100 adolescents (aged 12-17). Primary endpoint is the change in Autism Behavioral Inventory (ABI)-Social Communication Domain Score from baseline to Week 12. Key secondary endpoints include change in CGI-I, ABI-C and Aberrant Behavior Checklist-Irritability (ABC-I) score from baseline to Week 12.공시 • May 01MapLight Therapeutics, Inc., Annual General Meeting, Jun 23, 2026MapLight Therapeutics, Inc., Annual General Meeting, Jun 23, 2026.Recent Insider Transactions Derivative • Apr 16Founder notifies of intention to sell stockChristopher Kroeger intends to sell 21k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of April. If the sale is conducted around the recent share price of US$27.02, it would amount to US$563k. For the year to December 2023, Christopher's total compensation was 7% salary and 93% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2025, Christopher's direct individual holding has increased from 6.02k shares to 148.86k. Company insiders have collectively sold US$674k more than they bought, via options and on-market transactions in the last 12 months.New Risk • Apr 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 11% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$286m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Significant insider selling over the past 3 months (US$1.4m sold).Recent Insider Transactions • Mar 03Co-Founder recently sold US$260k worth of stockOn the 24th of February, Robert Malenka sold around 14k shares on-market at roughly US$18.34 per share. This transaction amounted to 9.1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth US$636k. Robert has been a net seller over the last 12 months, reducing personal holdings by US$1.4m.Recent Insider Transactions Derivative • Feb 24Co-Founder notifies of intention to sell stockRobert Malenka intends to sell 11k shares in the next 90 days after lodging an Intent To Sell Form on the 23rd of February. If the sale is conducted around the recent share price of US$18.42, it would amount to US$207k. Since September 2025, Robert's direct individual holding has increased from 3.38k shares to 155.74k. Company insiders have collectively sold US$414k more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions • Feb 13Independent Director recently bought US$253k worth of stockOn the 10th of February, Timothy Garnett bought around 14k shares on-market at roughly US$17.89 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$16m more in shares than they have sold in the last 12 months.Recent Insider Transactions Derivative • Feb 12Co-Founder notifies of intention to sell stockRobert Malenka intends to sell 7k shares in the next 90 days after lodging an Intent To Sell Form on the 10th of February. If the sale is conducted around the recent share price of US$18.12, it would amount to US$120k. Since September 2025, Robert's direct individual holding has increased from 3.38k shares to 174.72k. Company insiders have collectively bought US$15m more than they sold, via options and on-market transactions, in the last 12 months.Recent Insider Transactions • Feb 01Co-Founder recently sold US$636k worth of stockOn the 30th of January, Robert Malenka sold around 34k shares on-market at roughly US$18.49 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Robert's only on-market trade for the last 12 months.Recent Insider Transactions Derivative • Jan 29Co-Founder notifies of intention to sell stockRobert Malenka intends to sell 7k shares in the next 90 days after lodging an Intent To Sell Form on the 28th of January. If the sale is conducted around the recent share price of US$18.65, it would amount to US$122k. Since September 2025, Robert's direct individual holding has increased from 3.38k shares to 31.67k. There has only been one transaction (US$16m purchase) from insiders over the last 12 months.공시 • Jan 09MapLight Therapeutics, Inc. Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Third Quarter of 2026MapLight Therapeutics, Inc. announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule. The company's Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia continues to enroll robust, and topline results are now expected in the third quarter of 2026. The ZEPHYR study is a randomized, double-blind, placebo-controlled trial that is expected to enroll 300 hospitalized adult participants with schizophrenia experiencing acute exacerbation of psychosis. In addition, following completion of enrollment in the Phase 2 IRIS trial for ML-004 in autism spectrum disorder, topline results for that study are now expected in the third quarter of 2026. The IRIS study is a double-blind, placebo-controlled trial that randomized approximately 160 adult and adolescent participants.공시 • Jan 05Maplight Therapeutics, Inc. Receives Fast Track Designation for ML-007C-Ma for Alzheimer's Disease PsychosisMapLight Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel M1/M4 muscarinic agonist, for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). The Fast Track process is intended to facilitate the development and expedite the review of investigational therapies for serious conditions with unmet medical need. A drug with Fast Track designation may be eligible for more frequent interactions with the FDA, as well as accelerated approval and priority review, if applicable criteria are met. In a Phase 1 clinical trial, ML-007C-MA demonstrated a generally favorable safety and tolerability profile with twice daily dosing in healthy elderly participants. Enrollment is currently ongoing in the Phase 2 VISTA study, a randomized, double-blind, placebo-controlled trial evaluating ML-007C-MA for the treatment of hallucinations and delays associated with ADP. MapLight expects to enroll 300 participants in the trial and report topline results in the second half of 2027.Recent Insider Transactions • Nov 02Independent Director recently bought US$16m worth of stockOn the 28th of October, Jim Trenkle bought around 953k shares on-market at roughly US$17.00 per share. This transaction amounted to 35% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Board Change • Oct 28High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. Founder, President, CEO & Director Chris Kroeger is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Oct 27MapLight Therapeutics, Inc. has completed an IPO in the amount of $250.75 million.MapLight Therapeutics, Inc. has completed an IPO in the amount of $250.75 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 14,750,000 Price\Range: $17 Discount Per Security: $1.19 Transaction Features: Reserved Share Offering; Sponsor Backed Offering이익 및 매출 성장 예측NasdaqGS:MPLT - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028N/A-297-208-231712/31/2027N/A-257-206-222712/31/2026N/A-246-243-22093/31/2026N/A-199-164-164N/A12/31/2025N/A-161-139-138N/A9/30/2025N/A-103-113-113N/A6/30/2025N/A-92-101-101N/A3/31/2025N/A-81-85-84N/A12/31/2024N/A-78-80-79N/A3/31/2024N/A-63-60-60N/A12/31/2023N/A-56-52-52N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: MPLT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: MPLT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: MPLT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: MPLT 은(는) 내년에 수익이 없을 것으로 예상됩니다.고성장 매출: MPLT 은(는) 내년에 수익이 없을 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: MPLT는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 19:36종가2026/05/26 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스MapLight Therapeutics, Inc.는 10명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Sumant Satchidanand KulkarniCanaccord GenuityAdam VogelCraig-Hallum Capital Group LLCRaghuram SelvarajuH.C. Wainwright & Co.7명의 분석가 더 보기
Recent Insider Transactions Derivative • May 05Founder notifies of intention to sell stockChristopher Kroeger intends to sell 236k shares in the next 90 days after lodging an Intent To Sell Form on the 4th of May. If the sale is conducted around the recent share price of US$30.70, it would amount to US$7.3m. For the year to December 2023, Christopher's total compensation was 3% salary and 97% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2025, Christopher's direct individual holding has increased from 6.02k shares to 325.10k. Company insiders have collectively sold US$674k more than they bought, via options and on-market transactions in the last 12 months.
공시 • May 04MapLight Therapeutics Announces Completion of Enrollment In Zephyr Phase 2 Trial And Updates Expected Timing of Topline ResultsMapLight Therapeutics, Inc. announced completion of enrollment in its Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia. The Company also announced completion of the final patient visit in its Phase 2 IRIS trial evaluating ML-004 for the treatment of autism spectrum disorder. The Company expects to report topline results from both Phase 2 trials by mid-August 2026. The Phase 2 ZEPHYR trial is a randomized, double-blind, placebo-controlled trial evaluating the efficacy, safety, and tolerability of ML-007C-MA in inpatient adult participants with schizophrenia experiencing an acute exacerbation of psychosis. 307 participants in the trial were randomized 1:1:1 to receive either placebo, ML-007C-MA 210/3 mg twice daily, or ML-007C-MA 330/6 mg once daily. Primary endpoint is the change in PANSS total score from baseline to Week 5. Key secondary endpoints include change in CGI-S score, PANSS-Marder positive and negative factor scores from baseline to Week 5. Exploratory endpoints include change in cognitive function, assessed across multiple domains commonly impacted in schizophrenia, from baseline to Week 5. The Phase 2 IRIS trial is a randomized, double-blind, placebo-controlled trial evaluating the efficacy, safety, and tolerability of ML-004 in adults and adolescents with autism spectrum disorder. 161 participants were randomized in the trial, consistent with enrollment target of over 100 adolescents (aged 12-17). Primary endpoint is the change in Autism Behavioral Inventory (ABI)-Social Communication Domain Score from baseline to Week 12. Key secondary endpoints include change in CGI-I, ABI-C and Aberrant Behavior Checklist-Irritability (ABC-I) score from baseline to Week 12.
공시 • May 01MapLight Therapeutics, Inc., Annual General Meeting, Jun 23, 2026MapLight Therapeutics, Inc., Annual General Meeting, Jun 23, 2026.
Recent Insider Transactions Derivative • Apr 16Founder notifies of intention to sell stockChristopher Kroeger intends to sell 21k shares in the next 90 days after lodging an Intent To Sell Form on the 15th of April. If the sale is conducted around the recent share price of US$27.02, it would amount to US$563k. For the year to December 2023, Christopher's total compensation was 7% salary and 93% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2025, Christopher's direct individual holding has increased from 6.02k shares to 148.86k. Company insiders have collectively sold US$674k more than they bought, via options and on-market transactions in the last 12 months.
New Risk • Apr 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 11% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$286m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change). Significant insider selling over the past 3 months (US$1.4m sold).
Recent Insider Transactions • Mar 03Co-Founder recently sold US$260k worth of stockOn the 24th of February, Robert Malenka sold around 14k shares on-market at roughly US$18.34 per share. This transaction amounted to 9.1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth US$636k. Robert has been a net seller over the last 12 months, reducing personal holdings by US$1.4m.
Recent Insider Transactions Derivative • Feb 24Co-Founder notifies of intention to sell stockRobert Malenka intends to sell 11k shares in the next 90 days after lodging an Intent To Sell Form on the 23rd of February. If the sale is conducted around the recent share price of US$18.42, it would amount to US$207k. Since September 2025, Robert's direct individual holding has increased from 3.38k shares to 155.74k. Company insiders have collectively sold US$414k more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions • Feb 13Independent Director recently bought US$253k worth of stockOn the 10th of February, Timothy Garnett bought around 14k shares on-market at roughly US$17.89 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$16m more in shares than they have sold in the last 12 months.
Recent Insider Transactions Derivative • Feb 12Co-Founder notifies of intention to sell stockRobert Malenka intends to sell 7k shares in the next 90 days after lodging an Intent To Sell Form on the 10th of February. If the sale is conducted around the recent share price of US$18.12, it would amount to US$120k. Since September 2025, Robert's direct individual holding has increased from 3.38k shares to 174.72k. Company insiders have collectively bought US$15m more than they sold, via options and on-market transactions, in the last 12 months.
Recent Insider Transactions • Feb 01Co-Founder recently sold US$636k worth of stockOn the 30th of January, Robert Malenka sold around 34k shares on-market at roughly US$18.49 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Robert's only on-market trade for the last 12 months.
Recent Insider Transactions Derivative • Jan 29Co-Founder notifies of intention to sell stockRobert Malenka intends to sell 7k shares in the next 90 days after lodging an Intent To Sell Form on the 28th of January. If the sale is conducted around the recent share price of US$18.65, it would amount to US$122k. Since September 2025, Robert's direct individual holding has increased from 3.38k shares to 31.67k. There has only been one transaction (US$16m purchase) from insiders over the last 12 months.
공시 • Jan 09MapLight Therapeutics, Inc. Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Third Quarter of 2026MapLight Therapeutics, Inc. announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are progressing ahead of schedule. The company's Phase 2 ZEPHYR trial evaluating ML-007C-MA for the treatment of schizophrenia continues to enroll robust, and topline results are now expected in the third quarter of 2026. The ZEPHYR study is a randomized, double-blind, placebo-controlled trial that is expected to enroll 300 hospitalized adult participants with schizophrenia experiencing acute exacerbation of psychosis. In addition, following completion of enrollment in the Phase 2 IRIS trial for ML-004 in autism spectrum disorder, topline results for that study are now expected in the third quarter of 2026. The IRIS study is a double-blind, placebo-controlled trial that randomized approximately 160 adult and adolescent participants.
공시 • Jan 05Maplight Therapeutics, Inc. Receives Fast Track Designation for ML-007C-Ma for Alzheimer's Disease PsychosisMapLight Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel M1/M4 muscarinic agonist, for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). The Fast Track process is intended to facilitate the development and expedite the review of investigational therapies for serious conditions with unmet medical need. A drug with Fast Track designation may be eligible for more frequent interactions with the FDA, as well as accelerated approval and priority review, if applicable criteria are met. In a Phase 1 clinical trial, ML-007C-MA demonstrated a generally favorable safety and tolerability profile with twice daily dosing in healthy elderly participants. Enrollment is currently ongoing in the Phase 2 VISTA study, a randomized, double-blind, placebo-controlled trial evaluating ML-007C-MA for the treatment of hallucinations and delays associated with ADP. MapLight expects to enroll 300 participants in the trial and report topline results in the second half of 2027.
Recent Insider Transactions • Nov 02Independent Director recently bought US$16m worth of stockOn the 28th of October, Jim Trenkle bought around 953k shares on-market at roughly US$17.00 per share. This transaction amounted to 35% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Board Change • Oct 28High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. Founder, President, CEO & Director Chris Kroeger is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Oct 27MapLight Therapeutics, Inc. has completed an IPO in the amount of $250.75 million.MapLight Therapeutics, Inc. has completed an IPO in the amount of $250.75 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 14,750,000 Price\Range: $17 Discount Per Security: $1.19 Transaction Features: Reserved Share Offering; Sponsor Backed Offering